Skip to main content
Fig.3 | Cancer Cell International

Fig.3

From: β-Elemene alleviates cisplatin resistance in oral squamous cell carcinoma cell via inhibiting JAK2/STAT3 pathway in vitro and in vivo

Fig.3

β-Ele enhanced cisplatin sensitivity via down-regulating JAK2/STAT3 signaling pathway. a The expression of p-JAK2 and p-STAT3 detected by western blot in Tca-8113-CDDP cells treated with β-Ele or/and cisplatin; b the proliferation of Tca-8113-CDDP cells treated with β-Ele + cisplatin, and JAK activator RO8191 detected by MTT assays. c The cell cycles of Tca-8113-CDDP cells treated with β-Ele + cisplatin, and JAK activator RO8191 detected flow cytometry assays; d the apoptosis rate of Tca-8113-CDDP cells treated with β-Ele + cisplatin, and JAK activator RO8191 detected flow cytometry assays. e The mRNA and protein expression of Bcl-2, Bax, and caspase-3 in the Tca-8113-CDDP cells treated with β-Ele + cisplatin, and JAK activator RO8191 detected by RT-qPCR and Western blot. f The expression of p-JAK2 and p-STAT3 in the Tca-8113-CDDP cells treated with β-Ele + cisplatin, and JAK activator RO8191 detected by Western blot.*P < 0.05, **P < 0.01, ***P < 0.001. CDDP cisplatin, β-Ele β-Elemene, OD optical density

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us